Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.68 |
| ▸ | MAOA | P21397 | 3/20 | 0.68 |
| ▸ | BCHE | P06276 | 2/20 | 0.68 |
| ▸ | ACHE | P22303 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | CASP3 | P42574 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.63 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.63 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4213688 | 0.89 | MAOB (0.68) | MAOBACHECYP3A4 | |
| SCHEMBL4213269 | 0.89 | MAOB (0.69) | MAOBMAOA | |
| SCHEMBL16552382 | 0.84 | MAOB (0.73) | MAOBMAOABCHEACHECYP3A4 | |
| SCHEMBL4209954 | 0.83 | BCHE (0.56) | MAOBMAOABCHEACHECYP3A4 | |
| Hydrochloric Acid SCHEMBL17923763 | 0.83 | MAOB (0.73) | MAOBMAOABCHEACHECYP3A4 | |
| SCHEMBL4211668 | 0.83 | — | — | |
| SCHEMBL17931588 | 0.82 | MAOB (0.74) | MAOBMAOABCHEACHECYP3A4 | |
| SCHEMBL4211377 | 0.81 | MAOB (0.68) | MAOBMAOABCHEACHECYP3A4 | |
| SCHEMBL4203723 | 0.80 | CA12 (0.71) | MAOBMAOANPC1CASP3RAB9A | |
| SCHEMBL4219789 | 0.79 | MAOB (0.72) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005436-A1 | Substituted Aminoalkyl- and Amidoalkyl-Benzopyran Derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-01-01 | — | — | US | disclosed |
| EP-1863784-A1 | SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006102958-A1 | SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005436-A1 | Substituted Aminoalkyl- and Amidoalkyl-Benzopyran Derivatives | MAOB, MAOA, AOC3 | MAOB 1/4885MAOA 2/4885BCHE 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.